FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology firm, has declared a quarterly dividend of $0.95 per common share. This dividend is scheduled to be paid on September 30, 2024, to shareholders of record as of September 9, 2024. The company has indicated an annual dividend rate of $3.80 per share.
BD, with over 70,000 employees worldwide, is recognized for its contribution to healthcare, providing innovative technology, services, and solutions. These advancements aid in clinical therapy for patients and enhance the clinical process for healthcare providers. The company's efforts are particularly geared towards supporting healthcare professionals by improving the safety and efficiency of care delivery, as well as facilitating disease detection and aiding in the development of new diagnostics and therapeutics.
With operations in nearly every country, BD collaborates with various organizations to tackle significant global health challenges. Their mission is to improve healthcare outcomes, reduce costs, and promote safety and accessibility. The company's dedication to healthcare innovation and its global presence underscore its role as a key player in the medical technology industry.
This dividend announcement is part of BD's ongoing commitment to provide value to its shareholders and reflects the company's stable financial position and confidence in its business strategy. The declaration of the dividend is based on a press release statement from BD and represents a continuation of the company's practice of returning capital to its investors.
For more information on BD's initiatives and partnerships in the healthcare sector, interested parties can visit the company's website or connect via professional networking platforms.
In other recent news, BD (Becton, Dickinson and Company), a global medical technology firm, has surpassed its greenhouse gas emissions reduction targets for the fiscal year 2023. The company achieved an 18 percent reduction in emissions, exceeding its goal by 5 percentage points. This accomplishment aligns with BD's commitment to reach net-zero emissions by the fiscal year 2050. The Science Based Targets initiative has approved BD's emissions reduction targets, validating the company's efforts.
Furthermore, BD reported a successful second fiscal quarter in 2024, with robust revenue growth and margin performance. A significant contributor to this success was the Alaris system, which saw first-half sales exceed the total sales of the previous fiscal year. In addition, BD announced the acquisition of Edwards Lifesciences (NYSE:EW)' Critical Care division for $4.2 billion, expected to enhance BD's portfolio of smart connected care solutions.
Goldman Sachs initiated coverage on BD stock with a Buy rating, based on the anticipation of above-market revenue growth driven by new product launches. The investment bank also projected a shift in BD's earnings momentum, resulting in a 10% earnings growth through the fiscal year 2027. These are recent developments in the company's operations.
InvestingPro Insights
BD (Becton, Dickinson and Company) (NYSE: BDX) has recently affirmed its commitment to shareholders with the announcement of its upcoming quarterly dividend. This move is supported by the company's strong financial health and strategic position within the medical technology market. Here are some key insights from InvestingPro that may interest investors:
InvestingPro Data shows that BD has a market capitalization of $67.61 billion, reflecting its significant presence in the healthcare industry. Its Price/Earnings (P/E) ratio stands at 51.23, which is high, suggesting that investors are willing to pay a premium for the company's earnings. This could be due to the company's consistent performance and the expectation of continued growth, as BD's net income is anticipated to increase this year, according to one of the InvestingPro Tips.
Moreover, BD's dividend yield is currently 1.64%, with a dividend growth of 4.4% over the last twelve months as of Q2 2024. This is in line with the company's long-standing history of dividend payments, having raised its dividend for 54 consecutive years, a testament to its financial resilience and commitment to providing shareholder value.
Investors looking for stability may find comfort in BD's low price volatility, as mentioned in another InvestingPro Tip. Additionally, the company is trading near its 52-week low, which might represent a potential entry point for long-term investors who believe in the company's fundamentals and industry leadership.
For those interested in further insights and tips on BD, InvestingPro offers additional information that could guide investment decisions. By using the coupon code PRONEWS24, investors can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription to access exclusive data and analysis. Visit https://www.investing.com/pro/BDX to explore more InvestingPro Tips, with 6 additional tips currently available for BD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.